Nightstar Therapeutics to Present at the Deutsche Bank 43rd Annual Health Care Conference
02 May 2018 - 11:00PM
Nightstar Therapeutics plc (NASDAQ:NITE), a clinical-stage gene
therapy company developing treatments for rare inherited retinal
diseases, today announced that the company will participate in the
Deutsche Bank 43rd Annual Health Care Conference on Tuesday, May 8
at 4:10 p.m. ET in Boston, MA.
To access the live webcast, please visit ir.nightstartx.com. A
replay of the webcast will be available on the Nightstar website
for two weeks following the conference.
About Nightstar
Nightstar is a leading clinical-stage gene therapy company
focused on developing and commercializing novel one-time treatments
for patients suffering from rare inherited retinal diseases that
would otherwise progress to blindness. Nightstar’s lead product
candidate, NSR-REP1, is currently in Phase 3 development for the
treatment of patients with choroideremia, a rare, degenerative,
genetic retinal disorder that has no current treatments. Results
from a Phase 1/2 trial of NSR-REP1 were published in The Lancet in
2014 and in The New England Journal of Medicine in 2016.
Nightstar’s second product candidate, NSR-RPGR, is currently being
evaluated in a Phase 1/2 clinical trial for the treatment of
patients with X-linked retinitis pigmentosa, an inherited X-linked
recessive retinal disease.
For more information about Nightstar or its clinical trials,
please visit www.nightstartx.com.
Contacts:Senthil Sundaram, Chief Financial
OfficerBrian Luque, Sr. Manager, Investor
Relationsinvestors@nightstartx.com
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Sep 2024 to Oct 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Oct 2023 to Oct 2024
Real-Time news about Nightstar Therapeutics Plc ADS (NASDAQ): 0 recent articles
More News Articles